interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development
EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).
The EU Clinical Trials Register currently displays
44299
clinical trials with a EudraCT protocol, of which
7353
are clinical trials conducted with subjects less than 18 years old.
The register also displays information on
18700
older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see
Frequently Asked Questions ).
9 result(s) found for: Bone meal.
Displaying page 1 of 1.
EudraCT Number: 2015-005585-32
Sponsor Protocol Number: 111111733104
Start Date*: 2016-06-24
Sponsor Name:Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen
Full Title: Synergy effect of the appetite hormone GLP-1 (LiragluTide) and Exercise on maintenance of weight loss and health after a low calorie diet - the S-LiTE randomized trial
Full Title: A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery.
Sponsor Name:Fundacion Publica Andaluza para la Gestion de la Investigacion en Salud de Sevilla
Full Title: Phase I, randomized, open design trial to evaluate the effect of food (fasting, fat meal and standard meal) on the pharmacokinetics of abiraterone acetate at reduced doses, compared with convention...
Medical condition: metastatic prostatic cancer after castration-resistant progression to docetaxel
Full Title: A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer
Medical condition: PIK3CA mutated, HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy.
Full Title: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas
Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma, Follicular
Lymphoma, Advanced solid tumor
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Typ...
Full Title: An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Medical condition: Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors
Disease:
Version
SOC Term
Classification Code
Term
Level
21.1
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10000880
Acute myeloid leukaemia
PT
27.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10028533
Myelodysplastic syndrome
PT
21.1
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10065252
Solid tumor
LLT
21.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10009018
Chronic myelomonocytic leukaemia
PT
Population Age: Adults, Elderly
Gender: Male, Female
Trial protocol:SK(Trial now transitioned)BG(Trial now transitioned)ES(Completed)LT(Completed)HU(Trial now transitioned)AT(Ongoing)FR(Completed)DE(Trial now transitioned)IT(Completed)RO(Trial now transitioned)
Trial results:(No results available)
EudraCT Number: 2011-001959-37
Sponsor Protocol Number: E7449-E044-101
Start Date*: 2011-10-17
Sponsor Name:Eisai Limited
Full Title: An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combinat...
Medical condition: Advanced solid tumors (including ovarian cancer, triple negative breast cancer, and advanced melanoma) and B-cell lymphomas
Disease:
Version
SOC Term
Classification Code
Term
Level
14.1
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10033130
Ovarian cancer NOS
LLT
14.1
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10027475
Metastatic breast cancer
LLT
14.1
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10003899
B-cell lymphoma
PT
14.1
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10045992
Unspecified leukemia
LLT
14.1
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sponsor Name:Bristol-Myers Squibb International Corporation
Full Title: An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole with Lapatinib + Letrozole in Recurrent or Metastatic Breast Cancer Patients Who Are Hormone Receptor Pos...
Medical condition: Locally recurrent or metastatic hormone receptor positive (HR+) breast cancer and either:
• HER2+ disease with progression while on adjuvant antiendocrine therapy or at any time after adjuvant anti...
Subscribe to this Search
To subscribe to the RSS feed for this search click
here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options:
Number of Trials to download:
Download Content:
Download Format:
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
• EEA CTAs: Date study was authorised to proceed • Outside EU/EEA: Date study was submitted in EudraCT